Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis
Top Cited Papers
- 1 January 2007
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 132 (1), 66-75
- https://doi.org/10.1053/j.gastro.2006.10.011
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitisAlimentary Pharmacology & Therapeutics, 2005
- A double‐blind dose‐escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitisAlimentary Pharmacology & Therapeutics, 2005
- Mesalamine delivery systems: do they really make much difference?Advanced Drug Delivery Reviews, 2005
- Medication nonadherence and the outcomes of patients with quiescent ulcerative colitisThe American Journal of Medicine, 2003
- Balsalazide Is Superior to Mesalamine in the Time to Improvement of Signs and Symptoms of Acute Mild-to-Moderate Ulcerative ColitisAmerican Journal of Gastroenterology, 2002
- A double‐blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitisAlimentary Pharmacology & Therapeutics, 2002
- Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitisAmerican Journal of Gastroenterology, 2001
- Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 monthsAlimentary Pharmacology & Therapeutics, 1998
- Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitisGastroenterology, 1998
- Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitisThe Lancet, 1992